Duration of effects of isradipine during twice daily therapy in angina pectoris

[1]  B. Chaitman,et al.  Double‐Blind, Dose‐Response, Placebo‐Controlled Multicenter Study of Nisoldipine: A New Second‐Generation Calcium Channel Blocker in Angina Pectoris , 1991, Circulation.

[2]  D. Waters.  Proischemic complications of dihydropyridine calcium channel blockers. , 1991, Circulation.

[3]  D. Cummings,et al.  The role of calcium channel blockers in the treatment of essential hypertension. , 1991, Archives of internal medicine.

[4]  J. Popma,et al.  Effects of intravenous isradipine on left ventricular performance during rapid atrial pacing in coronary artery disease. , 1990, The American journal of cardiology.

[5]  Sastry G. Pantula,et al.  A Simple Approach to Inference in Random Coefficient Models , 1989 .

[6]  I. V. Van Gelder,et al.  Electrophysiological Properties of Isradipine (PN200–110) in Humans , 1989, Journal of cardiovascular pharmacology.

[7]  W. Burger,et al.  Hemodynamic and antianginal effects during rest and exercise of intravenous isradipine, a new dihydropyridine calcium antagonist , 1989, Clinical cardiology.

[8]  A. Keller,et al.  A multicenter evaluation of the safety, tolerability, and efficacy of isradipine in the treatment of essential hypertension. , 1989, The American journal of medicine.

[9]  P. Rüegg,et al.  Safety and efficacy of isradipine, alone and in combination, in the treatment of angina pectoris. , 1989, The American journal of medicine.

[10]  A. Salel,et al.  Isradipine in the treatment of angina pectoris , 1988 .

[11]  J. Jaffe,et al.  Clinical pharmacokinetics of isradipine , 1988 .

[12]  U. Ruegg,et al.  Pharmacology of the new calcium antagonist isradipine and its metabolites , 1988 .

[13]  J. Parker,et al.  Efficacy of the calcium antagonist isradipine in angina pectoris , 1988, Cardiovascular Drugs and Therapy.

[14]  R. Blouin,et al.  The Pharmacokinetics of Oral Isradipine in Normal Volunteers , 1988, Journal of clinical pharmacology.

[15]  R. Hof,et al.  Selective effects of PN 200-110 (isradipine) on the peripheral circulation and the heart. , 1987, The American journal of cardiology.

[16]  S. Taylor,et al.  Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris. , 1987, The American journal of cardiology.

[17]  J. Pool,et al.  Antihypertensive activity of isradipine in humans: A new dihydropyridine calcium channel antagonist , 1986, Clinical pharmacology and therapeutics.

[18]  Y. Wada,et al.  Separation of the Coronary Vasodilator from the Cardiac Effects of PN 200–110, a New Dihydropyridine Calcium Antagonist, in the Dog Heart , 1985, Journal of cardiovascular pharmacology.

[19]  H. Vuorela,et al.  PN 200–110, A New Calcium Antagonist: Electrophysiological, Inotropic, and Chronotropic Effects on Guinea Pig Myocardial Tissue and Effects on Contraction and Calcium Uptake of Rabbit Aorta , 1984, Journal of cardiovascular pharmacology.

[20]  R. Bruce,et al.  Exercise stress testing in evaluation of patients with ischemic heart disease. , 1969, Progress in cardiovascular diseases.

[21]  F. Tse,et al.  Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man , 2004, European Journal of Clinical Pharmacology.

[22]  E. Sowton,et al.  Safety, tolerability and efficacy of PN 200-110, a new calcium antagonist in patients with angina and coronary heart disease , 2004, European Journal of Clinical Pharmacology.

[23]  W. Voelker,et al.  Myocardial properties of the new dihydropyridine calcium antagonist isradipine compared to nifedipine with or without additional beta blockade in coronary artery disease. , 1989, The American journal of cardiology.

[24]  C. Handler,et al.  Comparison of isradipine and nifedipine in chronic stable angina. , 1988, International journal of cardiology.